[go: up one dir, main page]

TR200200401T2 - PEG-IFN-a ile birlikte mikofenolat mofetil - Google Patents

PEG-IFN-a ile birlikte mikofenolat mofetil

Info

Publication number
TR200200401T2
TR200200401T2 TR2002/00401T TR200200401T TR200200401T2 TR 200200401 T2 TR200200401 T2 TR 200200401T2 TR 2002/00401 T TR2002/00401 T TR 2002/00401T TR 200200401 T TR200200401 T TR 200200401T TR 200200401 T2 TR200200401 T2 TR 200200401T2
Authority
TR
Turkey
Prior art keywords
ifn
peg
mycophenolate mofetil
treatment
therapeutically effective
Prior art date
Application number
TR2002/00401T
Other languages
English (en)
Inventor
Catherine Graves Mary
Ghristopher Pappas Stephen
Zahm Friederike
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of TR200200401T2 publication Critical patent/TR200200401T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mikofenolik asidin farmasötik açidan kabul edilebilir bir tuzu veya ön ilacindan terapötik olarak etkili bir miktar ile birlikte IFN-a veya PEG-IFN-a'dan terapötik olarak etkili bir miktarin karaciger hastaliklari hastalarinin tedavi edilmesi amaçli ilaçlarin üretilmesinde kullanilmasi. Bilesenler en azindan adi geçen hastanin dis kaninda bulunan HCV-RNA miktarini, tedavi bittikten sonra 24.haftada 100 kopya/ml'nin altina indirmek için yeterli bir süreyle birlikte verilir.
TR2002/00401T 1999-08-13 2000-08-08 PEG-IFN-a ile birlikte mikofenolat mofetil TR200200401T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99115950 1999-08-13
US18790700P 2000-03-08 2000-03-08

Publications (1)

Publication Number Publication Date
TR200200401T2 true TR200200401T2 (tr) 2002-06-21

Family

ID=29762814

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00401T TR200200401T2 (tr) 1999-08-13 2000-08-08 PEG-IFN-a ile birlikte mikofenolat mofetil

Country Status (14)

Country Link
EP (1) EP1220683A2 (tr)
JP (1) JP2003507339A (tr)
CN (1) CN1368887A (tr)
AU (1) AU7408200A (tr)
BR (1) BR0013252A (tr)
CA (1) CA2380653A1 (tr)
HU (1) HUP0202525A3 (tr)
MX (1) MXPA02001296A (tr)
PE (1) PE20010490A1 (tr)
PL (1) PL357367A1 (tr)
RU (1) RU2002105485A (tr)
TR (1) TR200200401T2 (tr)
WO (1) WO2001012214A2 (tr)
ZA (1) ZA200200280B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
MX2007001663A (es) * 2004-08-12 2007-04-10 Schering Corp Formulacion de interferon pegilado estable.
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8623348B2 (en) * 2009-03-27 2014-01-07 Jw Pharmaceutical Corporation Interferon-α (IFN-α) fused proteins comprising IFN-α and a cytoplasmic transduction peptide (CTP)
SE1450019A1 (sv) 2011-10-21 2014-01-10 Abbvie Inc Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
CA2811250C (en) 2011-10-21 2015-08-11 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SI3215193T1 (sl) * 2014-11-06 2024-02-29 Pharmaessentia Corporation Dozirna shema za pegiliran interferon
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
HUP0202525A2 (hu) 2002-11-28
CA2380653A1 (en) 2001-02-22
WO2001012214A3 (en) 2001-10-04
PL357367A1 (en) 2004-07-26
PE20010490A1 (es) 2001-04-27
HUP0202525A3 (en) 2003-11-28
MXPA02001296A (es) 2002-07-22
RU2002105485A (ru) 2004-01-27
WO2001012214A2 (en) 2001-02-22
ZA200200280B (en) 2003-04-11
BR0013252A (pt) 2002-04-16
JP2003507339A (ja) 2003-02-25
CN1368887A (zh) 2002-09-11
AU7408200A (en) 2001-03-13
EP1220683A2 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
RU2003119460A (ru) Применение пэг-интерферона-а(пэг-inf-а) и рибавирина для лечения хронического гепатита с
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
TR200200401T2 (tr) PEG-IFN-a ile birlikte mikofenolat mofetil
DK275488D0 (da) Indolonderivater
KR920700200A (ko) 19-노르-비타민 d 화합물
PT779805E (pt) Libertacao sustentada de peptidos de composicoes farmaceuticas
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
ES2089027T3 (es) Forma de dosificacion transmucosica.
IL112667A0 (en) 6-substituted derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
ATE87484T1 (de) Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
TR200101633T2 (tr) Farmasötik bileşim
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2000041504A3 (en) Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
KR970025615A (ko) 암 전이 억제제
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
RU2004137823A (ru) Терапевтическое средство против гиперкальциемического криза
JP2002544227A5 (tr)
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
RU2004131214A (ru) Способы лечения когнитивных расстройств
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
KR890012942A (ko) 5-치환된 오르니틴 유도체